HSAP-Participated Project Approved for National Key R&D Program Empowering Early Screening and Treatment of Alzheimer's Disease with Original Technologies
Recently, the project titled "Research on Early Screening, Intervention System, and Validation for Alzheimer's Disease Based on Non-invasive Brain-Computer Interface" (Project No.: 2025YFE0218700), led by Professor Liu Xiuling from Hebei University, has been successfully approved for the 2025 Joint R&D and Demonstration Project under the National Key R&D Program's "Strategic Science and Technology Innovation Cooperation" initiative. The project carries a total funding of 8 million yuan. As a core participating entity, Qinhuangdao HSAP Medical Systems Co., Ltd. will leverage its technological expertise and industrial transformation capabilities in brain-computer interfaces and cognitive impairment screening/intervention. The company will deeply engage in tackling key technological challenges and implementing outcomes for this national-level project, providing an original Chinese industrial solution for the early prevention and control of Alzheimer's disease (AD).
This newly approved National Key R&D Program project focuses on three core technical bottlenecks in early AD screening, precision diagnosis, and intervention therapy, aiming to overcome the limitations of traditional diagnostic and therapeutic models. The project will pioneer a multi-modal physiological signal coupling analysis system integrating eye-brain-heart data alongside an early AD screening protocol, addressing the industry pain point of insufficient sensitivity in single-modality detection. simultaneously introducing an innovative personalized intervention paradigm integrating virtual reality neurotraining with targeted physical stimulation to establish a closed-loop "screening-diagnosis-intervention" technology chain. This aligns closely with Huisi Anpu's R&D focus in cognitive health and represents a significant achievement stemming from the company's long-standing commitment to "technology innovation driving industrial development."
As China's leading manufacturer of whole-life-cycle mind-body health management devices, HSAP has, since its 2011 founding, leveraged core technologies like bioimpedance, bionic pulse magnetic resonance, and brain-computer interfaces to pioneer precision prevention and treatment of neurological disorders. Its independently developed ADDS Cognitive Impairment Screening System and ADTS Memory Impairment Training System have achieved nationwide clinical deployment across multiple provinces and cities. The ADDS system employs non-invasive brain-computer interface technology combined with proprietary AI deep learning algorithms to rapidly quantify assessments across six cognitive dimensions, achieving screening accuracy exceeding 90%. It meets the precise diagnostic demands of top-tier hospitals while also supporting large-scale population screening in primary healthcare facilities. The ADTS system acts as a "personalized brain coach," enabling mind-controlled rehabilitation training through BCI technology to establish a comprehensive cognitive health maintenance model: "assessment-training-reassessment." By participating in this national-level project, Huisi Anpu will integrate its mature technology products and clinical application experience into project development, contributing to the optimization and upgrading of multimodal screening technology and the validation of personalized intervention paradigms.
This project brings together top-tier domestic scientific research and medical resources, spearheaded by Hebei University in collaboration with multiple institutions including the State Key Laboratory of Cognitive Neuroscience and Learning at Beijing Normal University, the National Key Laboratory of Multimodal Artificial Intelligence Systems at the Institute of Automation, Chinese Academy of Sciences, the National Medical Center for Neurological Diseases at Xuanwu Hospital, Capital Medical University, and the Key Laboratory of Brain Health Intelligence Assessment and Intervention under the Ministry of Education at Beijing Institute of Technology. As the sole corporate participant, HSAP will fully leverage its role as a bridge for industry-academia-research collaboration to accelerate the industrialization and clinical adoption of project outcomes. This will enable rapid transition from "laboratory technology" to "clinically viable products," making innovative early-stage AD prevention and control technologies accessible to broader populations.
"The project's approval under the National Key R&D Program signifies the state's high recognition of HSAP's technological strength and innovation capabilities," stated an HSAP representative. The company will leverage this collaboration to intensify R&D investments in brain-computer interfaces and neurodisease prevention, deeply integrating cutting-edge technologies like AI and neuromodulation to refine its end-to-end product ecosystem spanning "screening-intervention-rehabilitation." Moving forward, HSAP will uphold its responsibilities as a high-tech enterprise, leveraging original scientific breakthroughs to address challenges in Alzheimer's prevention and treatment. The company will provide core equipment support for establishing a nationwide cognitive health prevention network for the elderly, contributing its expertise to advance China's healthy aging initiatives.